





In This Issue

- **Fabrazyme® Update**
- **FIN Board NEWS**
- **NEW FIN Website**
- **FIN MAB / EFWG Report**
- **Industry Partner News**



Fabrazyme® Update



To meet the demand on supply update issues, FIN has created a subpage under "what is fabry" where you can find information on how to be directed to the Genzyme Fabrazyme® website: [Genzyme update](#).

FIN is here to Serve, Unite and Represent its members as a collective voice. Please keep in contact with concerns in your region:

[CONTACT US](#)

FIN Board News

FIN has recently undergone some internal change. Due to health reasons Erica Schenk has resigned as the Vice President of FIN. FIN gratefully acknowledges Erica her dedication to Fabry patients and the importance of caring for women with Fabry Disease. We wish her good health and rest at this time with her family. Lut de Baere has also stepped down as current President of FIN due to health reasons remaining on the FIN Board. FIN thanks Lut for continual dedication to serve the Fabry patient community and her contributions as leader of FIN. Until the FIN AGM 2012 whereby all FIN Board positions are declared vacant and nominations are filled, the FIN Board is now structured as follows;

FIN President:	Megan Fookes
FIN Vice President (U.S Portfolio):	Jack Johnson
FIN Vice President (European Portfolio):	Dennis Pedersen
FIN Secretary:	Christine Lavery
FIN Treasurer:	Kees Bosman
FIN Board Members:	Lut de Baere, Anna Meriluoto & one vacancy.

NEW FIN Website! www.fabryintnetwork.com

FIN is very proud to announce its new website is up and running! Please take a look and we welcome your feedback! [Fabry International Network](#)

FIN MAB / EFWG Report



Medical Advisory Board (MAB) representative; Dr Gabor Linthorst of The Netherlands, attended alongside 24 other European Fabry doctors a meeting in London (a few months back) to form the 'European Fabry Working Group.' [Read report](#).

Dr Waldek has resigned his position with the MAB with FIN. The Board of FIN would like to thank him very much for his support of the last few years.

FIN Industry Partner News

FIN Industry Partners will contribute to FIN's monthly E News with current relevant Fabry information.



FIN has uploaded into the website Amicus' latest Winter 2011 Patient Advocacy Newsletter [Amicus Winter Newsletter](#).

Amicus and GSK issued a [Press Release](#), announcing the start of the ATTRACT Study, AT 1001-012. This is a Phase 3 global clinical study to assess and efficacy and safety of migalastat HCl in individuals with Fabry Disease who currently receive ERT. Further information including study criteria can be found at [Clinical Trials](#)



Following feedback from FIN and the community, Genzyme has developed Frequently Asked Questions for the Fabry community in order to address questions regarding the current situation on global Fabrazyme® allocations and manufacturing.

Fabry patient groups are encouraged to contact their local Genzyme representative, to discuss translation of this document and to answer questions about Fabrazyme® availability in your country. Patients should always consult with their treating physician for the latest information. [Read FAQ's](#)



Ever since Shire's first patient began treatment in 1997 Shire has been dedicated to providing service and support to Fabry patients, their physicians and health care teams. Today Replagal® is commercially available in 47 countries and is being used to treat over 2700 patients worldwide, which represents more than 70% of the treated Fabry population.

Shire is committed to ensuring patients currently on Replagal will continue to have uninterrupted access to their treatment at the licensed dose. Shire's activities in 2011 have focused on meeting the increased global demand for Replagal during the Fabrazyme® supply shortage. Included in the treated patient population on Replagal, they are providing product to more than 140 patients in the United States. This year Shire introduced a new drug substance manufacturing facility, located at 400 Shire Way (400SW), Lexington, MA, USA. The European Medicines Agency (EMA) approved this manufacturing facility in June, several months earlier than expected, for the purification of Replagal® for Fabry disease. This approval increases manufacturing flexibility (two facilities will now be used for drug substance purification) and provide enhanced supply flexibility.